Is this you? Create Your Porfile

Dirk Reinhold

Otto-von-Guericke University Magdeburg

Archive Network Publication Hotspot Collaboration

Hotspot

Bubble
[Coming Soon]

Cloud

Mosaic
[Coming Soon]

Journal of Neuroimmunology | 1998

Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones

Dirk Reinhold; Bernhard Hemmer; Bruno Gran; Ilona Born; Jürgen Faust; Klaus Neubert; Henry F. McFarland; Roland Martin; Siegfried Ansorge

The ectoenzyme dipeptidyl peptidase IV (DP IV, EC 3.4.14.5, CD26) has been shown to play a crucial role in T cell activation. Specific inhibitors of DP IV suppress DNA synthesis as well as cytokine production (IL-2, IL-10, IL-12, IFN-gamma) of stimulated human and mouse T cells suggesting a potential application of these effectors in transplantations and autoimmune diseases. In the present study, we have examined the expression of DP IV/CD26 on six myelin basic protein (MBP)(87-99)-specific, CD4+ T cell clones (TCC) derived from patients with multiple sclerosis (MS) as well as the biological effects of the two synthetic DP IV inhibitors Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide on the function of these cells. All TCC expressed high levels of DP IV/CD26, as shown by flow cytometry and by enzymatic DP IV assay. Enzymatic activity of resting TCC was found to be three to fourfold higher than on resting peripheral blood T cells and close to that of T cells 48 h after PHA stimulation. The DP IV inhibitors suppress DNA synthesis and IFN-gamma, IL-4, and TNF-alpha production of the antigen-stimulated TCC. These data suggest that CD26 plays a role in regulation of activation of autoreactive TCC. Further in-vivo investigations, first in experimental models, will clarify, whether the inhibition of the enzymatic activity of DP IV could be a useful tool for therapeutic interventions in MS or other autoimmune diseases.

Archive | 2001

Combinations of enzyme inhibitor-containing preparations and the use thereof

Siegfried Ansorge; Marco Arndt; Frank Buehling; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Stefan Brocke

Archive | 2001

Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and a prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type I according to the gell and coombs classification and for the treatment and prevention of dermatological diseases associated with fo

Siegfried Ansorge; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Robert Vetter; Harald Gollnick

Archive | 2003

Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states

Siegfried Ansorge; Harald Gollnick; Klaus Neubert; Christos C. Zouboulis; Juergen Faust; Uwe Lendeckel; Dirk Reinhold; Robert Vetter

Archive | 2004

Use of dp iv and apn inhibitors for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts

Siegfried Ansorge; Harald Gollnick; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Robert Vetter; Burkhart Schraven; Anja Thielitz; Jürgen Faust

Archive | 2001

Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors

Siegfried Ansorge; Harald Gollnick; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Robert Vetter

Archive | 2003

Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit Hyperproliferation und veränderten Differenzierungszuständen von Fibroblasten

Siegfried Ansorge; Jürgen Dr. Faust; Harald Prof. Dr. Gollnick; Uwe Lendeckel; Klaus Prof. Dr. Neubert; Dirk Reinhold; Burkhart Prof. Dr. Schraven; Anja Thielitz; Robert Vetter

Archive | 2001

Combinations of enzyme inhibitors and the use thereof

Siegfried Ansorge; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Robert Vetter; Harald Gollnick

Archive | 2000

Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen

Klaus Neubert; Uwe Lendeckel; Siegfried Ansorge; Frank Buehling; Dirk Reinhold; Marco Arndt

Archive | 2007

Combined use of enzyme inhibitors and of pharmaceutical compositions thereof

Siegfried Ansorge; Uwe Lendeckel; Klaus Neubert; Dirk Reinhold; Robert Vetter; Harald Gollnick

Explore More